CORONA vs GKSL: Stock Comparison
Corona Remedies Ltd vs Gujarat Kidney & Super Speciality Ltd
Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings
Corona Remedies Ltd is the larger company by market capitalisation. Corona Remedies Ltd shows a higher ROE, a higher dividend yield and a higher ROCE, while Gujarat Kidney & Super Speciality Ltd shows a lower P/E, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Corona Remedies Ltd and Gujarat Kidney & Super Speciality Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | CORONA | GKSL |
|---|---|---|
| Live Price | ₹2,113 | ₹128.2 |
| Day Change | 4.1% | 0.71% |
| Volume | 61,596 | 73,624 |
| 52-Week High | ₹2,128.4 | ₹148.34 |
| 52-Week Low | ₹1,336.6 | ₹98.36 |
| Distance from 52W High | -0.72% | -13.58% |
Valuation
| Metric | CORONA | GKSL |
|---|---|---|
| Market Cap | ₹12,934 Cr | ₹1,013 Cr |
| P/E Ratio | 69.21x | 65.23x |
| P/B Ratio | 17.16x | 4.01x |
| EPS | ₹30.3 | ₹1.97 |
| Book Value | ₹122 | ₹32 |
| Dividend Yield | 0.49% | 0% |
Growth
| Metric | CORONA | GKSL |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 20.2% | 213% |
| Qtr Profit Growth | 43.7% | 294% |
Profitability & Leverage
| Metric | CORONA | GKSL |
|---|---|---|
| ROE | 29.5% | 11.1% |
| ROCE | 33.3% | 14.5% |
| Net Margin | 13.19% | 20.5% |
| Operating Margin | 21% | 32.8% |
| Debt to Equity | 0.22x | 0.12x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CORONA | GKSL |
|---|---|---|
| Promoter Holding | 69% | 71.45% |
| FII Holding | 3.63%▲ 1.38 pp | 4.88%▼ 5.59 pp |
| DII Holding | 12.9%▲ 5.88 pp | 0.56%▼ 1.11 pp |
| Public Holding | 14.48%▼ 7.26 pp | 23.1%▲ 6.7 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Corona Remedies Ltd and Gujarat Kidney & Super Speciality Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.